{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:02:13Z","timestamp":1787500933441,"version":"build-2736575974"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Many new cancer drugs are being approved by reputed regulatory authorities without evidence of overall survival benefit, quality of life improvement, and often based on clinical trials at high risk of bias. In recent years, most Latin American (LA) countries have reformed their marketing authorization (MA) rules to directly accept or abbreviate the approval process in case of earlier authorization by the European Medicines Agency (EMA) and the US Food and Drug Administration, mainly. This study assessed the potential impact of decisions taken by EMA regarding the approval of new cancer drugs based on no evidence of overall survival or in potentially biased clinical trials in LA countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Descriptive analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Publicly accessible marketing authorization databases from LA regulators, European Public Assessment Report by EMA, and previous studies accessing EMA approvals of new cancer drugs 2009\u20132016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Main outcome and measures<\/jats:title>\n                    <jats:p>Number of new cancer drugs approved by LA countries without evidence of overall survival (2009\u20132013), and without at least one clinical trial scored at low risk of bias, or with no trial supporting the marketing authorization at all (2014\u20132016).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Argentina, Brazil, Chile, Colombia, Ecuador, Panama and Peru have publicly accessible and trustful MA databases and were included. Of the 17 cancer drugs approved by EMA (2009\u20132013) without evidence of OS benefit after a postmarketing median time of 5.4 years, 6 LA regulators approved more than 70% of them. Of the 13 drugs approved by EMA (2014\u20132016), either without supporting trial or with no trial at low risk of bias, Brazil approved 11, Chile 10, Peru 10, Argentina 10, Colombia 9, Ecuador 9, and Panama 8.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec006\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LA countries keep approving new cancer drugs often based on poorly performed clinical trials measuring surrogate endpoints. EMA and other reputed regulators must be aware that their regulatory decisions might directly influence decisions regarding MA, health budgets and patient\u2019s care elsewhere.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0254585","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T13:28:50Z","timestamp":1626182930000},"page":"e0254585","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Potential negative impact of reputed regulators\u2019 decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1853-3641","authenticated-orcid":true,"given":"Carlos E.","family":"Dur\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0500-5866","authenticated-orcid":true,"given":"Mart\u00edn","family":"Ca\u00f1\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Urtasun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Elseviers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vander Stichele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Christiaens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"pone.0254585.ref001","doi-asserted-by":"crossref","first-page":"j4528","DOI":"10.1136\/bmj.j4528","article-title":"Do cancer drugs improve survival or quality of life?","volume":"359","author":"V Prasad","year":"2017","journal-title":"BMJ"},{"key":"pone.0254585.ref002","first-page":"10","article-title":"Flawed evidence underpins approval of new cancer","volume":"5399","author":"B Mintzes","year":"2019","journal-title":"BMJ"},{"key":"pone.0254585.ref003","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: Retrospective cohort study of drug approvals 2009\u20132013","volume":"359","author":"C Davis","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"pone.0254585.ref004","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jamainternmed.2020.1097","article-title":"FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992\u20132019.","volume":"180","author":"E Chen","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"6","key":"pone.0254585.ref005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/esmoopen-2016-000125","article-title":"Between January 2009 and April 2016, 134 novel anticancer therapies were approved: What is the level of knowledge concerning the clinical benefit at the time of approval?","volume":"1","author":"N Gr\u00f6ssmann","year":"2016","journal-title":"ESMO Open"},{"issue":"12","key":"pone.0254585.ref006","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","article-title":"Unintended Consequences of Expensive Cancer Therapeutics\u2014The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture.","volume":"140","author":"T Fojo","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"12","key":"pone.0254585.ref007","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US Food and Drug Administration approvals.","volume":"175","author":"C Kim","year":"2015","journal-title":"JAMA Inter Med"},{"issue":"8","key":"pone.0254585.ref008","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jval.2019.03.007","article-title":"Selection of Endpoints in Clinical Trials: Trends in European Marketing Authorization Practice in Oncological Indications.","volume":"22","author":"A Kordecka","year":"2019","journal-title":"Value Health"},{"issue":"5","key":"pone.0254585.ref009","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.bjc.6602750","article-title":"Ten years of marketing approvals of anticancer drugs in Europe: Regulatory policy and guidance documents need to find a balance between different pressures","volume":"93","author":"G Apolone","year":"2005","journal-title":"Br J Cancer"},{"key":"pone.0254585.ref010","doi-asserted-by":"crossref","first-page":"I5221","DOI":"10.1136\/bmj.l5221","article-title":"Design characteristics, risk of bias, and reporting of randomised controlled trials supporting European Medicines Agency approvals of cancer drugs, 2014\u20132016: cross-sectional analysis","volume":"366","author":"H Naci","year":"2019","journal-title":"BMJ"},{"issue":"8","key":"pone.0254585.ref011","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamainternmed.2020.2250","article-title":"Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration","volume":"180","author":"T Hilal","year":"2020","journal-title":"JAMA Inter Med"},{"issue":"11","key":"pone.0254585.ref012","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/jamainternmed.2013.627","article-title":"Characteristics of oncology clinical trials: Insights from a systematic analysis of clinicaltrials.gov","volume":"173","author":"BR Hirsch","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"2","key":"pone.0254585.ref013","doi-asserted-by":"crossref","first-page":"104","DOI":"10.21149\/spm.v58i2.7779","article-title":"Cancer patterns, trends and projections in Latin America and the Caribbean: A global context.","volume":"58","author":"F Bray","year":"2016","journal-title":"Salud Publ Mex"},{"key":"pone.0254585.ref014","doi-asserted-by":"crossref","first-page":"l6017","DOI":"10.1136\/bmj.l6017","article-title":"EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients","volume":"367","author":"CE Dur\u00e1n","year":"2019","journal-title":"BMJ"},{"key":"pone.0254585.ref015","first-page":"e10","article-title":"Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries.","volume":"45","author":"CE Dur\u00e1n","year":"2021","journal-title":"Rev Panam Salud Publica"},{"issue":"6","key":"pone.0254585.ref016","doi-asserted-by":"crossref","first-page":"e0157756","DOI":"10.1371\/journal.pone.0157756","article-title":"Health and Ethical Consequences of Outsourcing Pivotal Clinical Trials to Latin America: A Cross-Sectional, Descriptive Study.","volume":"11","author":"N Homedes","year":"2016","journal-title":"PLoS One"},{"issue":"1\u20132","key":"pone.0254585.ref017","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1017\/S0266462315000094","article-title":"Implications of Global Pricing Policies on Access to Innovative Drugs: The Case of Trastuzumab in Seven Latin American Countries.","volume":"31","author":"A Pichon-Riviere","year":"2015","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"pone.0254585.ref018","first-page":"1","article-title":"Judicializaci\u00f3n del acceso a medicamentos en el contexto Sudam\u00e9ricano.","volume":"20","author":"A Acosta","year":"2019","journal-title":"R Dir Sanit, S\u00e3o Paulo"},{"issue":"1","key":"pone.0254585.ref019","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12939-019-0960-z","article-title":"Judicialization of access to medicines in four Latin American countries: A comparative qualitative analysis.","volume":"18","author":"CM Vargas-Pelaez","year":"2019","journal-title":"Int J Equity Health"},{"key":"pone.0254585.ref020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.socscimed.2014.08.042","article-title":"Right to health, essential medicines, and lawsuits for access to medicines\u2014A scoping study.","volume":"121","author":"CM Vargas-Pel\u00e1ez","year":"2014","journal-title":"Soc Sci Med"},{"issue":"3","key":"pone.0254585.ref021","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1590\/S1020-49892013000300008","article-title":"Litigios por derecho a la salud en tres pa\u00edses de Am\u00e9rica Latina: revisi\u00f3n sistem\u00e1tica de la literatura.","volume":"33","author":"L Reveiz","year":"2013","journal-title":"Rev Panam Salud Publica"},{"issue":"4","key":"pone.0254585.ref022","doi-asserted-by":"crossref","first-page":"e0174616","DOI":"10.1371\/journal.pone.0174616","article-title":"Trends in medicines procurement by the Brazilian federal government from 2006 to 2013.","volume":"12","author":"T Chama Borges Luz","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"pone.0254585.ref023","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jphs.12221","article-title":"Sharp rise in the expenditures of targeted drugs in Ecuador: five-year (2010\u20132014) consumption of oncologic drugs in public and private hospitals.","volume":"9","author":"CE Dur\u00e1n","year":"2018","journal-title":"J Pharm Health Serv Res"},{"issue":"3","key":"pone.0254585.ref024","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000446537","article-title":"Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.","volume":"19","author":"L Leyens","year":"2016","journal-title":"Public Health Genomics"},{"issue":"1","key":"pone.0254585.ref025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdv506","article-title":"Early market access of cancer drugs in the EU","volume":"27","author":"J Martinalbo","year":"2016","journal-title":"Ann Oncol"},{"key":"pone.0254585.ref026","article-title":"Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.","author":"JC Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"pone.0254585.ref027","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.2019.21793","article-title":"Regulating Medicines in a Globalized World With Increased Recognition and Reliance Among Regulators: A National Academies Report","volume":"324","author":"LO Gostin","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"pone.0254585.ref028","first-page":"558","article-title":"Collaboration, not competition: developing new reliance models.","volume":"30","author":"R Luigetti","year":"2016","journal-title":"WHO Drug Information"},{"key":"pone.0254585.ref029","unstructured":"Considerations for effective regulatory reliance\u2014an Industry perspective [Internet]. Geneva; 2019. Available from: www.ifpma.org"},{"issue":"1","key":"pone.0254585.ref030","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S1470-2045(14)70375-4","article-title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future.","volume":"16","author":"MK Wilson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0254585.ref031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework.","volume":"69","author":"Biomarkers Definition Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0254585.ref032","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: When are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"R Kemp","year":"2017","journal-title":"BMC Medicine"},{"issue":"4","key":"pone.0254585.ref033","first-page":"498","article-title":"[Primary and Secondary Outcomes in Oncology Clinical Trials: Definitions and Uses].","volume":"27","author":"A Vaz-Carneiro","year":"2014","journal-title":"Acta Med Port"},{"key":"pone.0254585.ref034","unstructured":"Clinton B, Gore A. Reinventing the regulation of cancer drugs: accelerating approval and expanding of oncology drugs. 1996. Available from: https:\/\/books.google.be\/books\/about\/Reinventing_the_Regulation_of_Cancer_Dru.html?id=URm7D02FhUQC&redir_esc=y"},{"key":"pone.0254585.ref035","doi-asserted-by":"crossref","first-page":"m770","DOI":"10.1136\/bmj.m770","article-title":"Inappropriate use of progression-free survival in cancer drug approvals","volume":"368","author":"H Naci","year":"2020","journal-title":"BMJ"},{"issue":"7","key":"pone.0254585.ref036","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.","volume":"179","author":"B Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"key":"pone.0254585.ref037","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","volume":"106","author":"A Haslam","year":"2019","journal-title":"Eur J Cancer"},{"issue":"12","key":"pone.0254585.ref038","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis.","volume":"178","author":"B Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"7","key":"pone.0254585.ref039","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ijc.31957","article-title":"Association between progression-free survival and patients\u2019 quality of life in cancer clinical trials","volume":"144","author":"TJ Hwang","year":"2019","journal-title":"Int J Cancer"},{"key":"pone.0254585.ref040","doi-asserted-by":"crossref","first-page":"100332","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA\u2019s table of surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"B Gyawali","year":"2020","journal-title":"EClinicalMedicine"},{"key":"pone.0254585.ref041","unstructured":"Pan American Health Organization. Regulatory reliance principles: concept note and recommendations. In: Ninth Conference of the Pan American Network for Drug Regulatory Harmonization (PANDRH), San Salvador, 24 to 26 October, 2018. Washington, D.C.: PAHO; 2019."},{"issue":"2","key":"pone.0254585.ref042","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.yrtph.2010.04.001","article-title":"Granting marketing authorisation for medicines in South East European countries: The point of view of the authority.","volume":"57","author":"S Tomi\u0107","year":"2010","journal-title":"Regul Toxicol Pharmacol"},{"issue":"6","key":"pone.0254585.ref043","first-page":"383","article-title":"Medicines Regulation in Africa: Current State and Opportunities.","volume":"31","author":"M Ndomondo-Sigonda","year":"2017","journal-title":"Pharmaceut Med"},{"issue":"2","key":"pone.0254585.ref044","doi-asserted-by":"crossref","first-page":"e001912","DOI":"10.1136\/bmjgh-2019-001912","article-title":"Addressing the challenges of regulatory systems strengthening in small states","volume":"5","author":"C Preston","journal-title":"BMJ Global Health 2020"},{"issue":"2","key":"pone.0254585.ref045","doi-asserted-by":"crossref","first-page":"e1000411","DOI":"10.1371\/journal.pmed.1000411","article-title":"Registering new drugs for low-income countries: The African challenge.","volume":"8","author":"M Moran","year":"2011","journal-title":"PLoS Medicine"},{"key":"pone.0254585.ref046","first-page":"e1962","article-title":"Therapeutic value and price of the new pharmaceuticals commercialized in Argentina: Are they worth what they cost?","volume":"15","author":"M Ca\u00f1\u00e1s","year":"2019","journal-title":"Salud Colectiva"},{"issue":"12)","key":"pone.0254585.ref047","doi-asserted-by":"crossref","first-page":"djw163","DOI":"10.1093\/jnci\/djw163","article-title":"Distribution and Patterns of Industry-Related Payments to Oncologists in 2014","volume":"108","author":"DC Marshall","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"pone.0254585.ref048","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1634\/theoncologist.2018-0423","article-title":"Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology.","volume":"24","author":"AP Mitchell","year":"2019","journal-title":"Oncologist"},{"key":"pone.0254585.ref049","doi-asserted-by":"crossref","first-page":"100283","DOI":"10.1016\/j.jcpo.2021.100283","article-title":"Industry payments to US physicians for cancer therapeutics: An analysis of the 2016\u20132018 open payments datasets.","volume":"28","author":"Daniel E. Meyers","year":"2021","journal-title":"Journal of Cancer Policy"},{"issue":"4","key":"pone.0254585.ref050","doi-asserted-by":"crossref","first-page":"e203284","DOI":"10.1001\/jamanetworkopen.2020.3284","article-title":"Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995\u20132017.","volume":"3","author":"AD Zhang","year":"2020","journal-title":"JAMA Network Open"},{"issue":"2","key":"pone.0254585.ref051","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/1468-0009.12261","article-title":"Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.","volume":"95","author":"H Naci","year":"2017","journal-title":"Milbank Q"},{"issue":"3","key":"pone.0254585.ref052","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/17512433.2020.1724782","article-title":"The European Medicines Agency facilitates access to medicines in low- and middle-income countries","volume":"13","author":"M Cavaller Bellaubi","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"pone.0254585.ref053","doi-asserted-by":"crossref","first-page":"e003181","DOI":"10.1136\/bmjgh-2020-003181","article-title":"The WHO Global Benchmarking Tool: a game changer for strengthening national regulatory capacity","volume":"5","author":"J Guzman","journal-title":"BMJ Glob Health 2020"},{"key":"pone.0254585.ref054","doi-asserted-by":"crossref","first-page":"i5792","DOI":"10.1136\/bmj.i5792","article-title":"Cancer drugs, survival, and ethics","volume":"355","author":"P Wise","year":"2016","journal-title":"BMJ"},{"key":"pone.0254585.ref055","doi-asserted-by":"crossref","first-page":"h2068","DOI":"10.1136\/bmj.h2068","article-title":"Why do cancer drugs get such an easy ride?","volume":"350","author":"DW Light","year":"2015","journal-title":"BMJ"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0254585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T13:30:00Z","timestamp":1626183000000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0254585"}},"subtitle":[],"editor":[{"given":"Vadim E.","family":"Degtyar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":55,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0254585","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]}}}